REMS: The New Secret to Product Success?
FDA-mandated Risk Evaluation and Mitigation Strategies (REMS) are often viewed as obstacles to product access. Having supported more than 100 REMS programs, UBC has a different perspective. We view REMS programs as paths to prescriber loyalty and commercial success.
Submit your information using the form below to gain immediate access to the free whitepaper, “100 REMS Programs and Counting – Top Lessons Learned,” authored by leading industry expert, Annette Stemhagen, DrPH, FISPE, Senior Vice President, Safety, Epidemiology, Registries, and Risk Management.